Global Intravenous Immunoglobulin Market by Indication (Primary Immunodeficiency, Secondary Immunodeficiency), Form (Liquid IVIG, Lyophilized IVIG), End-User - Forecast 2024-2030- Product Image

Sale

Global Intravenous Immunoglobulin Market by Indication (Primary Immunodeficiency, Secondary Immunodeficiency), Form (Liquid IVIG, Lyophilized IVIG), End-User - Forecast 2024-2030

Report
190 Pages
March 2024
Region: Global
360iResearch™
ID: 5889544

UP TO €845EUR$875USD£723GBP OFF until Dec 31^st 2024

The Intravenous Immunoglobulin Market size was estimated at USD 1.25 billion in 2023, USD 1.33 billion in 2024, and is expected to grow at a CAGR of 6.92% to reach USD 1.99 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Intravenous Immunoglobulin Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Intravenous Immunoglobulin Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Intravenous Immunoglobulin Market, highlighting leading vendors and their innovative profiles. These include ADMA Biologics, Inc., Baxter International, Inc., Bayer HealthCare LLC, Biotest AG by Grifols S.A., CSL Behring, Johnson & Johnson Services, Inc., Kedrion S.p.A., LFB Biotechnologies, Octapharma AG, and Option Care Health, Inc.

Market Segmentation & Coverage

This research report categorizes the Intravenous Immunoglobulin Market to forecast the revenues and analyze trends in each of the following sub-markets:

Indication
- Primary Immunodeficiency
- Secondary Immunodeficiency
Form
- Liquid IVIG
- Lyophilized IVIG
End-User
- Homecare Facilities
- Hospitals & Clinics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

What is the market size and forecast of the Intravenous Immunoglobulin Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the Intravenous Immunoglobulin Market?
What are the technology trends and regulatory frameworks in the Intravenous Immunoglobulin Market?
What is the market share of the leading vendors in the Intravenous Immunoglobulin Market?
Which modes and strategic moves are suitable for entering the Intravenous Immunoglobulin Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Intravenous Immunoglobulin Market, by Region

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Surge in the prevalence of chronic inflammatory demyelinating polyneuropathy (CIDP) and hypogammaglobulinemia
5.1.1.2. Significant rise in geriatric population and number of hemophilic patients
5.1.1.3. Rising use of off-label indications in intravenous immunoglobulin products
5.1.2. Restraints
5.1.2.1. Stringent government regulations toward the use of intravenous immunoglobulin products
5.1.3. Opportunities
5.1.3.1. Emergence of improved technologies in immunoglobulin production
5.1.3.2. Increasing number of intravenous immunoglobulin product approvals
5.1.4. Challenges
5.1.4.1. High risk of side effects associated with intravenous immunoglobulin products
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization

6. Intravenous Immunoglobulin Market, by Indication

6.1. Introduction
6.2. Primary Immunodeficiency
6.3. Secondary Immunodeficiency

7. Intravenous Immunoglobulin Market, by Form

7.1. Introduction
7.2. Liquid IVIG
7.3. Lyophilized IVIG

8. Intravenous Immunoglobulin Market, by End-User

8.1. Introduction
8.2. Homecare Facilities
8.3. Hospitals & Clinics

9. Americas Intravenous Immunoglobulin Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Intravenous Immunoglobulin Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Intravenous Immunoglobulin Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

13.1. Key Company Profiles
13.1.1. ADMA Biologics, Inc.
13.1.2. Baxter International, Inc.
13.1.3. Bayer HealthCare LLC
13.1.4. Biotest AG by Grifols S.A.
13.1.5. CSL Behring
13.1.6. Johnson & Johnson Services, Inc.
13.1.7. Kedrion S.p.A.
13.1.8. LFB Biotechnologies
13.1.9. Octapharma AG
13.1.10. Option Care Health, Inc.
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing

List of Figures

FIGURE 1. INTRAVENOUS IMMUNOGLOBULIN MARKET RESEARCH PROCESS
FIGURE 2. INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, 2022 VS 2030
FIGURE 3. INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. INTRAVENOUS IMMUNOGLOBULIN MARKET DYNAMICS
FIGURE 7. INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2022 VS 2030 (%)
FIGURE 8. INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2022 VS 2030 (%)
FIGURE 10. INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2022 VS 2030 (%)
FIGURE 12. INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 14. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 16. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 21. INTRAVENOUS IMMUNOGLOBULIN MARKET, FPNV POSITIONING MATRIX, 2022
FIGURE 22. INTRAVENOUS IMMUNOGLOBULIN MARKET SHARE, BY KEY PLAYER, 2022

List of Tables

TABLE 1. INTRAVENOUS IMMUNOGLOBULIN MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 6. INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 9. INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LIQUID IVIG, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LYOPHILIZED IVIG, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 12. INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOMECARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 15. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 16. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 17. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 18. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 19. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 20. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 21. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 22. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 23. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 24. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 25. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 26. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 27. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 28. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 29. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 30. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 31. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 32. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 33. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 34. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 35. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 36. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 37. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 38. AUSTRALIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 39. AUSTRALIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 40. AUSTRALIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 41. CHINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 42. CHINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 43. CHINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 44. INDIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 45. INDIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 46. INDIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 47. INDONESIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 48. INDONESIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 49. INDONESIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 50. JAPAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 51. JAPAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 52. JAPAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 53. MALAYSIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 54. MALAYSIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 55. MALAYSIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 56. PHILIPPINES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 57. PHILIPPINES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 58. PHILIPPINES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 59. SINGAPORE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 60. SINGAPORE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 61. SINGAPORE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 62. SOUTH KOREA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 63. SOUTH KOREA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 64. SOUTH KOREA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 65. TAIWAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 66. TAIWAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 67. TAIWAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 68. THAILAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 69. THAILAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 70. THAILAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 71. VIETNAM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 72. VIETNAM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 73. VIETNAM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 74. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 75. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 78. DENMARK INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 79. DENMARK INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 80. DENMARK INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 81. EGYPT INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 82. EGYPT INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 83. EGYPT INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 84. FINLAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 85. FINLAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 86. FINLAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 87. FRANCE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 88. FRANCE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 89. FRANCE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 90. GERMANY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 91. GERMANY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 92. GERMANY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 93. ISRAEL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 94. ISRAEL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 95. ISRAEL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 96. ITALY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 97. ITALY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 98. ITALY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 99. NETHERLANDS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 100. NETHERLANDS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 101. NETHERLANDS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 102. NIGERIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 103. NIGERIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 104. NIGERIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 105. NORWAY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 106. NORWAY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 107. NORWAY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 108. POLAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 109. POLAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 110. POLAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 111. QATAR INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 112. QATAR INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 113. QATAR INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 114. RUSSIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 115. RUSSIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 116. RUSSIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 117. SAUDI ARABIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 118. SAUDI ARABIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 119. SAUDI ARABIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 120. SOUTH AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 121. SOUTH AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 122. SOUTH AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 123. SPAIN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 124. SPAIN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 125. SPAIN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 126. SWEDEN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 127. SWEDEN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 128. SWEDEN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 129. SWITZERLAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 130. SWITZERLAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 131. SWITZERLAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 132. TURKEY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 133. TURKEY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 134. TURKEY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 135. UNITED ARAB EMIRATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 136. UNITED ARAB EMIRATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 137. UNITED ARAB EMIRATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 138. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 140. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 141. INTRAVENOUS IMMUNOGLOBULIN MARKET, FPNV POSITIONING MATRIX, 2022
TABLE 142. INTRAVENOUS IMMUNOGLOBULIN MARKET SHARE, BY KEY PLAYER, 2022
TABLE 143. INTRAVENOUS IMMUNOGLOBULIN MARKET LICENSE & PRICING

Companies Mentioned

ADMA Biologics, Inc.
Baxter International, Inc.
Bayer HealthCare LLC
Biotest AG by Grifols S.A.
CSL Behring
Johnson & Johnson Services, Inc.
Kedrion S.p.A.
LFB Biotechnologies
Octapharma AG
Option Care Health, Inc.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	190
Published	March 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 1.33 Billion
Forecasted Market Value ( USD ) by 2030	$ 1.99 Billion
Compound Annual Growth Rate	6.9%
Regions Covered	Global
No. of Companies Mentioned	10

PURCHASE OPTIONS

Single User License Online Access - 1 Year

Single User License PDF, Excel And Online Access - 1 Year

1 - 5 User License PDF, Excel And Online Access - 1 Year

Site License PDF, Excel And Online Access - 1 Year

Enterprise License PDF, Excel And Online Access - 1 Year

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€3259EUR$3,374USD£2,787GBP €3621EUR$3,749USD£3,097GBP
SINGLE USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€4129EUR$4,274USD£3,530GBP €4587EUR$4,749USD£3,923GBP
1 - 5 USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a 1-5 user license, allowing up to five users have access to the product.	€4998EUR$5,174USD£4,274GBP €5553EUR$5,749USD£4,749GBP
SITE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5867EUR$6,074USD£5,017GBP €6519EUR$6,749USD£5,575GBP
ENTERPRISE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is an enterprise license, allowing all employees within your organization access to the product.	€7606EUR$7,874USD£6,504GBP €8451EUR$8,749USD£7,227GBP

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects:

The report addresses key questions such as:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Intravenous Immunoglobulin Market Size, Share & Trends Analysis Report By Application (Hypogammaglobulinemia, CIDP, Congenital AIDS), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030

Intravenous Immunoglobulin Global Market Report 2024

Intravenous Immunoglobulin Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Intravenous Immunoglobulin Market Report: Trends, Forecast and Competitive Analysis to 2030

Intravenous Immunoglobulin (IVIg): Global Strategic Business Report

About the Intravenous Immunoglobulin Market